Bellicum Pharmaceuticals Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bellicum Pharmaceuticals in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Bellicum Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BLCM, but not buy additional shares or sell existing shares.
View analyst ratings for Bellicum Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Bellicum Pharmaceuticals a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Bellicum Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Bellicum Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Bellicum Pharmaceuticals.

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) issued its earnings results on Monday, May, 17th. The biopharmaceutical company reported ($1.08) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($1.37) by $0.29.
View Bellicum Pharmaceuticals' earnings history.

Bellicum Pharmaceuticals' stock was trading at $7.29 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, BLCM shares have decreased by 59.5% and is now trading at $2.95.
View which stocks have been most impacted by COVID-19.

Bellicum Pharmaceuticals shares reverse split before market open on Thursday, February 6th 2020. The 1-10 reverse split was announced on Wednesday, February 5th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, February 5th 2020. An investor that had 100 shares of Bellicum Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

2 analysts have issued 12-month price objectives for Bellicum Pharmaceuticals' shares. Their forecasts range from $4.50 to $4.50. On average, they anticipate Bellicum Pharmaceuticals' stock price to reach $4.50 in the next year. This suggests a possible upside of 52.5% from the stock's current price.
View analysts' price targets for Bellicum Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Some companies that are related to Bellicum Pharmaceuticals include Gain Therapeutics (GANX), IMARA (IMRA), Otonomy (OTIC), Acasti Pharma (ACST), Yumanity Therapeutics (YMTX), Aileron Therapeutics (ALRN), Aprea Therapeutics (APRE), Rezolute (RZLT), Eledon Pharmaceuticals (ELDN), Moleculin Biotech (MBRX), Evofem Biosciences (EVFM), Aeterna Zentaris (AEZS), Liminal BioSciences (LMNL), Entasis Therapeutics (ETTX) and Graybug Vision (GRAY).
View all of BLCM's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Bellicum Pharmaceuticals investors own include Arrowhead Pharmaceuticals (ARWR), Alliance Resource Partners (ARLP), AVEO Pharmaceuticals (AVEO), TransEnterix (TRXC), CyberArk Software (CYBR), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Novavax (NVAX), Pfizer (PFE) and Inovio Pharmaceuticals (INO).

(BLCM) raised $101 million in an IPO on Thursday, December 18th 2014. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Jefferies, Citigroup and Piper Jaffray served as the underwriters for the IPO and Trout Capital was co-manager.

Bellicum Pharmaceuticals trades on the NASDAQ under the ticker symbol "BLCM."

Shares of BLCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BLCM stock can currently be purchased for approximately $2.95.

Bellicum Pharmaceuticals has a market capitalization of $24.77 million and generates $500,000.00 in revenue each year. The biopharmaceutical company earns $-7,720,000.00 in net income (profit) each year or ($3.66) on an earnings per share basis.

Bellicum Pharmaceuticals employs 10 workers across the globe.

The official website for Bellicum Pharmaceuticals is www.bellicum.com.

Bellicum Pharmaceuticals is headquartered at 2130 WEST HOLCOMBE BOULEVARD SUITE 800, HOUSTON TX, 77030.

Bellicum Pharmaceuticals' mailing address is 2130 WEST HOLCOMBE BOULEVARD SUITE 800, HOUSTON TX, 77030. The biopharmaceutical company can be reached via phone at (832) 384-1100 or via email at [email protected]